<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006100</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068109</org_study_id>
    <secondary_id>PSCI-2003-257</secondary_id>
    <secondary_id>UAB-0002</secondary_id>
    <secondary_id>NCI-G00-1829</secondary_id>
    <nct_id>NCT00006100</nct_id>
  </id_info>
  <brief_title>Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I Pilot Trial to Evaluate the Toxicity of Epstein-Barr Virus Specific T-Lymphocytes or Peripheral Blood Mononuclear Cells for the Treatment of Relapsed/Refractory Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing. Donor white blood cells that are treated in the laboratory with&#xD;
      Epstein-Barr virus may be effective treatment for Hodgkin's lymphoma.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of allogeneic Epstein-Barr virus-specific&#xD;
      cytotoxic T cells in treating patients who have progressive, relapsed, or refractory&#xD;
      Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity of allogeneic Epstein Barr virus (EBV)-specific cytotoxic&#xD;
           T-lymphocytes (EBV CTL) in patients with progressive, relapsed, or refractory&#xD;
           EBV-positive Hodgkin's lymphoma.&#xD;
&#xD;
        -  Detect alterations in the anti-EBV cellular immunity of patients treated with EBV CTL.&#xD;
&#xD;
      OUTLINE: Donors undergo leukapheresis. Epstein Barr virus-specific cytotoxic T lymphocytes&#xD;
      (EBV CTL) are cultured in vitro.&#xD;
&#xD;
      Patients receive an infusion of EBV CTL over 10 minutes on day 0. The EBV CTL infusion is&#xD;
      preceded by 3 doses of fludarabine. Patients then receive interleukin-2 injections for 12&#xD;
      days after the EBV CTL infusion.&#xD;
&#xD;
      Patients are followed weekly for 1.5 months, twice a month for 1.5 months, and then monthly&#xD;
      for 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2000</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven Hodgkin's lymphoma&#xD;
&#xD;
               -  Progressive, relapsed, or refractory disease after prior chemotherapy,&#xD;
                  radiotherapy, and/or stem cell transplantation&#xD;
&#xD;
               -  Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2&#xD;
                  OR the presence of EBV RNA (EBER)&#xD;
&#xD;
          -  Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes,&#xD;
             meeting the following criteria:&#xD;
&#xD;
               -  EBV seropositive&#xD;
&#xD;
               -  HIV negative&#xD;
&#xD;
               -  HTLV-1 negative&#xD;
&#xD;
               -  Hepatitis B surface antigen and hepatitis B core antibody IgM negative&#xD;
&#xD;
               -  Hepatitis C antibody negative&#xD;
&#xD;
               -  Must share at least 1 HLA haplotype with donor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT less than 2.5 times normal (unless liver metastases are present)&#xD;
&#xD;
               -  If there is liver involvement by disease, an obvious relationship between&#xD;
                  SGOT/SGPT and disease activity is required&#xD;
&#xD;
          -  No hepatic dysfunction causing moribundity&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
          -  No renal dysfunction causing moribundity&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac dysfunction causing moribundity&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary dysfunction causing moribundity&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No neurologic dysfunction causing moribundity&#xD;
&#xD;
          -  No history of severe transfusion reactions with blood products (including fetal calf&#xD;
             serum)&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent antimetabolites&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth G. Lucas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004 May 1;100(9):1892-901. doi: 10.1002/cncr.20188.</citation>
    <PMID>15112270</PMID>
  </results_reference>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

